Showing session: reset
Clinical Trials Using PARP Inhibitors
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer
Joaquin Mateo
The Institute of Cancer Research & The Royal Marsden NHS Trust, London, United Kingdom
- Permission not
granted for presentation
Discussant
William K. Kelly
Thomas Jefferson Univ. Kimmel Cancer Ctr., Philadelphia, PA, United States
- Permission not
granted for presentation
Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
Vasiliki Michalarea
Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
- Permission not
granted for presentation
Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
Ursula A. Matulonis
Dana-Farber Cancer Institute, Boston, MA, United States
- Permission not
granted for presentation
Discussant
Geoffrey I. Shapiro
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Combination of the PARP inhibitor veliparib (ABT888) with irinotecan in patients with triple negative breast cancer: Preliminary activity and signature of response
Patricia M. LoRusso
Yale Cancer Center, New Haven, CT, United States
- Permission not
granted for presentation
Pharmacokinetic/pharmacodynamic study of sequence specificity of the PARP inhibitor, olaparib and carboplatin in recurrent women’s cancers
Victoria L. Chiou
Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Yves G. Pommier
NCI-CCR, Bethesda, MD, United States